TopoTarget and CuraGen announce presentations on Belinostat at the upcoming American Society of Hematology 49th Annual Meeting

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com


To the OMX
Announcement No. 39-07 / Copenhagen, 26 November 2007


TopoTarget and CuraGen announce presentations on Belinostat at the upcoming
American Society of Hematology 49th Annual Meeting 



Copenhagen, Denmark - 26 November 2007 - TopoTarget A/S (OMX: TOPO) and CuraGen
Corporation (Nasdaq: CRGN) a clinical-stage biopharmaceutical company focused
on oncology, have announced today that updated preliminary clinical trial
results from the Phase II study of belinostat for T-cell lymphomas, and new
preclinical data evaluating belinostat on pediatric leukemia cell lines, will
be presented at the 2007 American Society of Hematology (ASH) 49th Annual
Meeting in Atlanta, GA, USA,  on Monday, December 10, 2007. 

The presentation details are as follows:

Title: 	“Belinostat (PXD101) in Patients with Recurrent or Refractory
Peripheral or Cutaneous T-Cell Lymphoma: Results of a Phase II Study” 
Date/Time: 	Monday, December 10, 2007, 5:00 - 7:00 PM EST
Session: 	Lymphoma: Chemotherapy, excluding Pre-Clinical Models-Diffuse Large
Cell Lymphoma and T-Cell Lymphoma 
Poster board: 	672-II
Abstract: 	3453

Title: 	“Investigation of the Efficacy of PXD101 (Belinostat) on Primary
Leukaemic Cells and Cell Lines as a Novel Agent for Childhood Acute
Lymphoblastic Leukaemia (ALL)” 
Date/Time: 	Monday, December 10, 2007, 5:00 - 7:00 PM EST
Session: Acute Lymphocytic Leukemia: Biology and Pathophysiology 
Poster board: 	12-III
Abstract: 	2793

These abstracts are currently available online at
http://www.abstracts2view.com/hem07.  Following the presentations the posters
will be made available on TopoTarget's website at www.topotarget.com. 

Today's news does not change TopoTarget's full-year financial guidance for 2007.


TopoTarget A/S

	
For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22

Ulla Hald Buhl 	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49




Background information

About Belinostat
Belinostat is a promising small molecule HDAC inhibitor being investigated for
its role in the treatment of a wide range of solid tumors and hematologic
malignancies either as a single-agent, or in combination with other active
anti-cancer agents, including carboplatin, paclitaxel, cis-retinoic acid,
azacitidine and Velcade® (bortezomib) for Injection.  HDAC inhibitors represent
a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes
and have been shown to arrest growth of cancer cells (including drug resistant
subtypes); induce apoptosis, or programmed cell death; promote differentiation;
inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance
when used in combination with other anti-cancer agents. 

Intravenous belinostat is currently being evaluated in multiple clinical trials
as a potential treatment for cutaneous and peripheral T-cell lymphomas, B-cell
lymphomas, AML, mesothelioma, soft tissue sarcoma, MDS, and liver, colorectal,
and ovarian cancers, either alone or in combination with anti- cancer
therapies.  An oral formulation of belinostat is also being evaluated in a
Phase I clinical trial for patients with advanced solid tumors.  In August
2004, CuraGen signed a Clinical Trials Agreement with the NCI under which the
NCI will sponsor several clinical trials to investigate belinostat for the
treatment of various cancers, both as a single-agent and in combination
chemotherapy regimens.  In May 2005, TopoTarget announced the signing of a
Cooperative Research and Development Agreement (CRADA) with the NCI to conduct
preclinical and nonclinical studies on belinostat in order to better understand
its anti-tumor activity and to provide supporting information for clinical
trials. 

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding
''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and nine drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com. 

About CuraGen
CuraGen Corporation (NASDAQ: CRGN) is a dedicated clinical-stage
biopharmaceutical company developing diverse approaches for the treatment of
cancer including the histone deacetylase inhibitor, belinostat, and the
antibody-drug conjugate, CR011-vcMMAE.  By leveraging drug development
strengths cultivated over the years, CuraGen expects to make a difference by
advancing its promising therapeutics to address the unmet medical needs of
cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut.
 For additional information please visit www.curagen.com. 
.

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.